Small molecule FLT3 tyrosine kinase inhibitors

Research output: Contribution to journalArticle

Abstract

Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential. All rights reserved -

Original languageEnglish (US)
Pages (from-to)399-416
Number of pages18
JournalFrontiers in Medicinal Chemistry
Volume3
Issue number1
StatePublished - 2006

Fingerprint

Protein-Tyrosine Kinases
Molecules
Acute Myeloid Leukemia
Contrast Media
Assays
Mutation
3-tyrosine

Keywords

  • AML
  • FLT3
  • Kinase inhibitor
  • Tyrosine kinase

ASJC Scopus subject areas

  • Organic Chemistry
  • Molecular Medicine
  • Drug Discovery
  • Pharmaceutical Science
  • Biochemistry

Cite this

Small molecule FLT3 tyrosine kinase inhibitors. / Levis, Mark J; Small, Donald.

In: Frontiers in Medicinal Chemistry, Vol. 3, No. 1, 2006, p. 399-416.

Research output: Contribution to journalArticle

@article{750ccb010e434c7b8d20744a2080e474,
title = "Small molecule FLT3 tyrosine kinase inhibitors",
abstract = "Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential. All rights reserved -",
keywords = "AML, FLT3, Kinase inhibitor, Tyrosine kinase",
author = "Levis, {Mark J} and Donald Small",
year = "2006",
language = "English (US)",
volume = "3",
pages = "399--416",
journal = "Frontiers in Drug Design and Discovery",
issn = "1574-2042",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Small molecule FLT3 tyrosine kinase inhibitors

AU - Levis, Mark J

AU - Small, Donald

PY - 2006

Y1 - 2006

N2 - Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential. All rights reserved -

AB - Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential. All rights reserved -

KW - AML

KW - FLT3

KW - Kinase inhibitor

KW - Tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=40249092034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40249092034&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 399

EP - 416

JO - Frontiers in Drug Design and Discovery

JF - Frontiers in Drug Design and Discovery

SN - 1574-2042

IS - 1

ER -